HAEMONETICS CORP - Common Stock (HAE)

Q3 2018 13F Holders as of 30 Sep 2018

Type / Class
Equity / Common Stock
Shares outstanding
47,898,935
Total 13F shares
51,715,308
Share change
+1,463,284
Total reported value
$5,924,362,043
Put/Call ratio
132%
Price per share
$114.58
Number of holders
289
Value change
+$210,878,544
Number of buys
119
Number of sells
191

Institutional Holders of HAEMONETICS CORP - Common Stock (HAE) as of Q3 2018

As of 30 Sep 2018, HAEMONETICS CORP - Common Stock (HAE) was held by 289 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 51,715,308 shares. The largest 10 holders included BlackRock Inc., Vanguard Group Inc, WELLINGTON MANAGEMENT GROUP LLP, RENAISSANCE TECHNOLOGIES LLC, STATE STREET CORP, Capital Research Global Investors, Neuberger Berman Group LLC, Jackson Square Partners, LLC, DIMENSIONAL FUND ADVISORS LP, and DEUTSCHE BANK AG\. This page lists 289 institutional shareholders reporting positions in this security for the Q3 2018 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.